羊种布鲁氏菌对穿越血脑屏障的新型头孢菌素的体外敏感性
In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.
作者信息
Palenque E, Otero J R, Noriega A R
出版信息
Antimicrob Agents Chemother. 1986 Jan;29(1):182-3. doi: 10.1128/AAC.29.1.182.
Abstract
The in vitro susceptibilities of 83 clinical isolates of Brucella melitensis to seven cephalosporins and a monobactam were determined. Ceftizoxime, ceftriaxone, and cefotaxime were the most effective agents tested, with MICs ranging from 0.25 to 2 micrograms/ml. Moxalactam, cefoperazone, cefuroxime, and ceftazidime showed MICs between 4 and 64 micrograms/ml, with moxalactam being the most active agent in this group. Aztreonam showed poor activity, with MICs higher than 64 micrograms/ml.
摘要
测定了83株羊种布鲁氏菌临床分离株对7种头孢菌素和1种单环β-内酰胺类抗生素的体外敏感性。头孢唑肟、头孢曲松和头孢噻肟是测试中最有效的药物，其最低抑菌浓度（MIC）范围为0.25至2微克/毫升。拉氧头孢、头孢哌酮、头孢呋辛和头孢他啶的MIC在4至64微克/毫升之间，拉氧头孢是该组中活性最强的药物。氨曲南活性较差，MIC高于64微克/毫升。
相似文献
1
In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.羊种布鲁氏菌对穿越血脑屏障的新型头孢菌素的体外敏感性
Antimicrob Agents Chemother. 1986 Jan;29(1):182-3. doi: 10.1128/AAC.29.1.182.
2
3
Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.氨曲南和新型头孢菌素对罕见分离革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 1983 Aug;24(2):282-6. doi: 10.1128/AAC.24.2.282.
4
Comparative in vitro activity of 8 cephalosporins on 109 strains of Neisseria gonorrhoeae and 60 strains of Neisseria meningitidis.8种头孢菌素对109株淋病奈瑟菌和60株脑膜炎奈瑟菌的体外活性比较
Chemotherapy. 1981;27 Suppl 1:19-24. doi: 10.1159/000238024.
5
Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.七种广谱头孢菌素对血培养中革兰氏阴性杆菌的比较活性
J Antimicrob Chemother. 1985 Aug;16(2):183-8. doi: 10.1093/jac/16.2.183.
6
Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand.泰国淋病奈瑟菌的抗生素敏感性调查。
Antimicrob Agents Chemother. 1992 Aug;36(8):1682-7. doi: 10.1128/AAC.36.8.1682.
7
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
8
In vitro activity of ceftazidime and ceftriaxone.头孢他啶和头孢曲松的体外活性。
Clin Ther. 1983;5(6):603-16.
9
An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.新型头孢菌素的体外比较，特别涉及铜绿假单胞菌。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:97-105. doi: 10.1093/jac/8.suppl_b.97.
10
New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
Diagn Microbiol Infect Dis. 1992 Jan;15(1):73-80. doi: 10.1016/0732-8893(92)90059-3.
引用本文的文献
1
Efficacy evaluation of some antibiotics against syrian brucella spp isolates, in vitro.一些抗生素对叙利亚布鲁氏菌属分离株的体外疗效评价。
Braz J Microbiol. 2012 Oct;43(4):1269-73. doi: 10.1590/S1517-83822012000400005. Epub 2012 Jun 1.
2
In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.采用空斑试验测定头孢曲松和夫西地酸对13株贝氏柯克斯体的体外活性。
Antimicrob Agents Chemother. 1993 Mar;37(3):491-4. doi: 10.1128/AAC.37.3.491.
3
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.羊种布鲁氏菌体外抗菌药敏性与人类布鲁氏菌病复发率的相关性
Antimicrob Agents Chemother. 1986 Dec;30(6):958-60. doi: 10.1128/AAC.30.6.958.
4
Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.头孢曲松。对其抗菌活性和药代动力学特性的重新评估，以及关于其治疗用途的最新情况，特别提及每日一次给药。
Drugs. 1988 Jun;35(6):604-45. doi: 10.2165/00003495-198835060-00002.
本文引用的文献
1
Protean manifestations of nervous system brucellosis. Case histories of a wide variety of clinical forms.神经系统布鲁氏菌病的多种表现形式。各种临床类型的病例史。
JAMA. 1963 Apr 27;184:269-75. doi: 10.1001/jama.1963.03700170061009.
2
Antibiotic therapy of bacterial meningitis: lessons we've learned.细菌性脑膜炎的抗生素治疗：我们学到的经验教训。
Am J Med. 1981 Oct;71(4):507-10. doi: 10.1016/0002-9343(81)90191-1.
3
In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.与头孢西丁、利福平、四环素及复方新诺明相比，N-甲酰亚胺基硫霉素对98株羊种布鲁氏菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1982 Mar;21(3):501-3. doi: 10.1128/AAC.21.3.501.
4
The new beta-lactamase-stable cephalosporins.新型β-内酰胺酶稳定的头孢菌素。
Ann Intern Med. 1982 Sep;97(3):408-19. doi: 10.7326/0003-4819-97-3-408.
5
Human brucellosis.人类布鲁氏菌病
Rev Infect Dis. 1983 Sep-Oct;5(5):821-42. doi: 10.1093/clinids/5.5.821.
6
Treatment of bacterial meningitis with ceftizoxime.用头孢唑肟治疗细菌性脑膜炎。
Antimicrob Agents Chemother. 1984 Feb;25(2):258-62. doi: 10.1128/AAC.25.2.258.
7
Comparison of ceftriaxone and traditional therapy of bacterial meningitis.头孢曲松与细菌性脑膜炎传统疗法的比较。
Antimicrob Agents Chemother. 1984 Jan;25(1):40-4. doi: 10.1128/AAC.25.1.40.
8
Pharmacokinetic profile of ceftriaxone in man.头孢曲松在人体内的药代动力学特征。
Am J Med. 1984 Oct 19;77(4C):17-25.
9
In vitro susceptibility of Brucella to various antibiotics.布鲁氏菌对各种抗生素的体外敏感性。
Appl Microbiol. 1970 Oct;20(4):600-4. doi: 10.1128/am.20.4.600-604.1970.
10
Determination of the in vitro sensitivity of Brucella strains to rifampicin.布鲁氏菌菌株对利福平的体外敏感性测定。
Br Vet J. 1976 May-Jun;132(3):266-75. doi: 10.1016/s0007-1935(17)34686-9.
Zotero 插件